N/A N=160 Lifestyle Intervention for Weight Gain Management for Patients With Schizophrenia
Schizophrenia · Obesity
Primary: Change in Weight From Baseline to Endpoint — 0.48; 0.48 kg — p=0.055
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
Weight Gain
Primary: Change From Baseline to Week 24 in Body Mass Index (BMI) — 1.620; 1.800 kg/m^2
N/A N=144 Naltrexone for Antipsychotic-Induced Weight Gain
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight From Baseline — -0.16; 0.69; -0.95 kg — p=0.83
Phase 4 N=30 Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)
Medication Adherence · Bipolar Disorder
Primary: Treatment Non-adherence Percentage as Measured by the Tablet Routines Questionnaire (TRQ) — 16.11; 13.88 Percentage of doses
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs
Phase 2 N=40 Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight — -2.0021; -1.5490 kg. (killograms)
N/A N=8,493 Monitoring and Management for Metabolic Side Effects of Antipsychotics
Mental Health · Psychotic Disorders
Primary: Change in Site-level Rates of Weight Monitoring at Baseline (Within 30 Days of a New Antipsychotic Prescription) — 1811; 1410; 1598; 1109 Participants
Phase 4 N=51 Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
Schizophrenia · Type 2 Diabetes Mellitus
Primary: Change in Total Body Fat (kg). — 0.15; -1.77; -1.27 change in kilograms — p=0.03
Phase 4 N=127 Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
Psychotic Disorders
Primary: Body Mass Index (BMI) Z-score Change — 0.040; -0.112; -0.088 Z Score
Phase 4 N=146 The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
Schizophrenia
Primary: Mean Difference in Body Weight Change Between Participants Assigned to Metformin and Participants Assigned to Placebo — -1.0; -3.0 kilograms
Phase 4 N=23 Medication, Weight Gain and GI Hormones
Bipolar Depression
Primary: Weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 — 76.0; 76.1; 77.4; 77.6 kilograms
N/A N=96 Glucose and Lipid Metabolism on Antipsychotic Medication
Schizophrenia · Schizoaffective Disorder · Type 2 Diabetes Mellitus
Primary: DEXA Total Fat — 32.24; 27.66; 28.83; 31.60 kilograms of body fat — p=0.002
Phase 4 N=33 Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Diabetes
Primary: Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine — 37; 40.5 pounds
N/A N=49 Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: HDL Ratio — 39.7; 38.4; 43.5; 42.3 unit of Measure ''g/dL''
Phase 3 N=199 Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
Schizophrenia · Schizoaffective Disorders
Primary: Change From Baseline to Endpoint in Weight — 2.76; 2.40; 0.65 kilograms — p=0.065
Phase 4 N=37 Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
Schizophrenia
Primary: Change From Baseline in Weight — 1.7; 2.1 kilograms
Phase 4 N=144 Metabolic Effects of Antipsychotics in Children
Aggression · Attention Deficit-Hyperactivity · Oppositional Defiant Disorder
Primary: Change in DEXA % Body Fat — 1.81; 4.12; 1.66 percent body fat — p=<0.0001
N/A N=122 Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
Diabetes · Obesity · Weight Gain
Primary: Mean Weight — 235.22; 232.1; 235.95; 233.41 Pounds — p=<0.01
N/A N=12 Vitamin D Supplementation in Psychiatric Illnesses
Obesity · Vitamin D Deficiency · Psychosis
Primary: Change in Weight — 0.07 kilograms
N/A N=152 Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
Anorexia Nervosa
Primary: Rate of Weight Change — 0.095; 0.260 kg/m^2 per month
N/A N=4 Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight (in Lbs.) — 24.9 lbs.
Phase 4 N=215 Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks — -20.2; -10.8 mg/dL non-HDL cholesterol
Phase 4 N=31 Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
Healthy
Primary: Change in Body Weight — 3.2; 0.8; 0.4 kg
Phase 4 N=77 Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
Schizophrenia · Metabolic Syndrome X · Insulin Resistance
Primary: Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min) — 0.072; 0.407 (1/mU/L) x 1/Min — p=0.228
Phase 2 N=30 Diabetes in Neuropsychiatric Disorders
Schizophrenia
Primary: Body Mass Index — 22.1; 23.5; 24.2; 24.3 kg/m^2 — p=<0.001
Phase 4 N=23 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
Hypogonadism · Severe Obesity
Primary: Percent Change in Muscle Strength as Assessed by Knee Extension and Knee Flexion — 12.6; 8.9; 12.8; 3.7 Percent change in muscle strength
Phase 4 N=149 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Time Course of Change From Baseline in Body Mass Index (BMI) — 0.09; 0.16; 0.25; 0.27 kilograms/square meters — p=0.428
Phase 4 N=54 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
Weight Gain
Primary: Change in Weight From Baseline to Endpoint. — -1.1; 5.9 Pounds
Phase 1 N=76 A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
Healthy
Primary: Change From Baseline in Body Weight — 2.32; 4.23; 2.87 kilograms
Phase 2 N=34 Olanzapine in the Treatment of Patients With Anorexia Nervosa
Anorexia Nervosa
Primary: Body Mass Index (BMI) (kg/m^2) — 19.66; 20.30; 19.66; 20.30 kg/m^2